Mulberry Blood Glucose Randomized Trial: What the Evidence Says

Quick Answer

Mulberry Blood Glucose Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The estimated prevalence of diabetes in China significantly increased from 10.9% in 2013 to 12.4% in 2018. [Li Huiqin (2026); evidence level 2]
• Thus, SGLT2 inhibitors have an insulin-independent hypoglycemic mechanism through reduced renal glucose reabsorption. [Li Huiqin (2026); evidence level 2]
• As the disease progresses, most diabetic patients have a gradual decrease in pancreatic β-cell function and reduced ability to regulate blood glucose, resulting in large fluctuations in blood glucose levels, which can lead to long-term T2DM complications via activation of oxidative stress, exacerbation of inflammation, and damage to endothelial cells. [Zhou Yu (2026); evidence level 4]
• If the proportion of carbohydrates in a patient's diet is too high or digestion is too rapid, CSII alone may require a larger dose of pre-prandial insulin, which easily leads to increased postprandial blood glucose fluctuation or a risk of hypoglycemia in the late phase of the insulin action peak. [Zhou Yu (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For mulberry blood glucose randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Li Huiqin (2026). Effects of mulberry twig alkaloids and canagliflozin in inadequately controlled type 2 diabetes: a randomized controlled study based on flash glucose monitoring. DOI: 10.1038/s41598-026-48843-2. PMCID: PMC13265803. PMID: 42014890. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13265803/
• Zhou Yu (2026). Mulberry Twig Alkaloids Combined With Insulin Infusion: Effects on Blood Glucose Variability in Type 2 Diabetes. DOI: 10.12659/MSM.951024. PMCID: PMC13007452. PMID: 41845930. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13007452/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.